Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H4GB
|
|||
| Former ID |
DPR000027
|
|||
| Drug Name |
CB1 antagonist, Bayer
|
|||
| Synonyms |
2-[(2,6-dichloro-3-methylphenyl)amino]benzoate; CHEMBL876; CL-583.NA SALT; meclofenamic acid(1-); UPCMLD-DP012; AC1L1H9Q; UPCMLD-DP012:001; CTK5I4915; CHEBI:76230; BDBM50012896; MCULE-3600081195; CCG-204812; NCGC00023217-05; NCGC00023217-04; NCGC00023217-03; NCGC00023217-06; ZB000384; 2-(2,6-dichloro-3-methylanilino)benzoate; AB00053494; AB00053494_19; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate(Fenamate series)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Preclinical | [1] | |
| Company |
Bayer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H10Cl2NO2-
|
|||
| Canonical SMILES |
CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl
|
|||
| InChI |
1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)/p-1
|
|||
| InChIKey |
SBDNJUWAMKYJOX-UHFFFAOYSA-M
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:76230
|
|||
| SuperDrug ATC ID |
M01AG04
|
|||
| SuperDrug CAS ID |
cas=000644622
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.